ClinicalTrials.gg
Active, not recruitingNCT07946458LPP1Updated Nov 18, 2026

LIPI-PROTECT-1 : Dietary Supplement in Subjects With Moderate Hypercholesterolemia (LPP1)

An interventional study of LIPI-PROTECT-1 in Hypercholesterolemia / Elevated LDL Cholesterol, sponsored by Institut Pasteur de Lille. Active, not recruiting at 2 sites in France. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Institut Pasteur de Lille · Not applicable, Interventional, and Prevention

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 65 studies in Hypercholesterolemia with a site in France — 4 open to participants now, 10 under way, 5 of them phase 3. Hypercholesterolemia · France.

Enrollment
60th of 61
20 · median 300
Started
2026
the only one that year
No phase
15 of 65
3 open now
Registered
65th of 65
by date
Lead sponsor
3 of 65
Institut Pasteur de Lille

Among the 65 studies in Hypercholesterolemia with a site in France, this one is the 60th largest by enrollment of the 61 interventional ones that give a count, is the only one that started in 2026, is one of 15 with no phase, and was the 65th registered.

Hypercholesterolemia

1,179 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

4 of the 65 studies in Hypercholesterolemia with a site in France are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Hypercholesterolemia with a site in France, or all of them as a file.
02

Study summary

This is a multicenter, uncontrolled pilot study evaluating changes in plasma LDL-cholesterol (LDL-C) concentrations before and after 3 months of intake of the dietary supplement LIPI-PROTECT-1.

The main objective of this clinical trial is to evaluate the effect of LIPI-PROTECT-1 on plasma LDL-C concentration after 3 months of supplementation in participants with untreated moderate hypercholesterolemia.

A mean reduction in plasma LDL-C levels of approximately 14% (0.20 g/L) is expected after 3 months of supplementation.

The primary endpoint is the absolute (g/L) and relative (%) change in plasma LDL-C concentration between baseline and Month 3.

Read the detailed description

Elevated low-density lipoprotein cholesterol (LDL-C) is an established risk factor for coronary cardiovascular disease. In individuals at low cardiovascular risk, lifestyle and dietary measures are recommended to reduce LDL-C levels and/or overall cardiovascular risk. Dietary supplements may be considered as part of these measures when their efficacy has been demonstrated.

LIPI-PROTECT-1 is a dietary supplement containing plant extracts and vitamins that may contribute to reducing plasma LDL-C levels. Some of its individual active ingredients have previously been investigated in clinical studies and have shown an LDL-C-lowering effect. However, the combination of these active ingredients has not previously been evaluated in a clinical study.

This pilot, multicenter, uncontrolled study is designed to provide preliminary estimates of the effect of LIPI-PROTECT-1 in adults with untreated moderate hypercholesterolemia.

A total of 20 men and women aged 18 to 65 years with untreated moderate hypercholesterolemia will be included. Participants will have an LDL-C level ≥1.5 g/L and a low cardiovascular risk. They will consume LIPI-PROTECT-1 for 3 months and will be required to maintain stable body weight, dietary habits, and physical activity throughout the study.

The primary objective is to assess the effect of LIPI-PROTECT-1 on plasma LDL-C concentration after 3 months of supplementation. The primary outcome will be the absolute and relative change in LDL-C concentration between baseline and Month 3. A mean reduction of approximately 14% (0.20 g/L) in LDL-C is expected after 3 months of supplementation.

Secondary objectives are to evaluate the effect of LIPI-PROTECT-1 after 1 and 3 months compared with baseline on body weight, body mass index, waist circumference, systolic and diastolic blood pressure, resting heart rate, fasting glucose, LDL-C, non-HDL cholesterol, total cholesterol, HDL cholesterol, triglycerides, LDL-C/HDL-C and total cholesterol/HDL-C ratios, and the atherogenic index (non-HDL-C/HDL-C).

Safety will also be assessed by comparing selected laboratory parameters between baseline and Month 3, including AST, ALT, gamma-glutamyl transferase, creatine kinase, lactate dehydrogenase, bilirubin, creatinine, and urea. Adherence to the dietary supplement will be assessed throughout the study.

Participants with high or very high cardiovascular risk, lipid-lowering treatment, diabetes, severe chronic diseases, or concomitant treatments likely to interfere with the assessment of efficacy or safety will be excluded.

03

Conditions studied

  • Hypercholesterolemia / Elevated LDL Cholesterol

Keywords

  • Hypercholesterolemia
  • Elevated LDL Cholesterol
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Men and women aged 18-65 years

For women :

If pre-menopausal: effective non-estrogenic* initiated at least 2 cycles prior and maintained throughout the study If : not receiving estrogenic* Hormone Replacement Therapy (HRT)

  • LDL-cholesterol ≥ 1.5 g/L (calculated using the Friedewald formula)
  • Aware of their hypercholesterolemia and previously informed about the associated lifestyle and dietary measures
  • between 20 and 35 kg/m² (inclusive)
  • Stable weight, dietary habits, and physical activity level for at least 3 months prior to the start of the study, with agreement to maintain them throughout the study
  • Willing to comply with study requirements
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Subjects receiving lipid-lowering or anti-dyslipidemic therapy (statins, ezetimibe, cholestyramine, fibrates, etc.)
  • Subjects with triglyceride levels > 4 g/L
  • Subjects requiring immediate lipid-lowering therapy
  • Subjects with diabetes (whether treated with medication or not, or diagnosed during the initial visit based on fasting blood glucose > 1.26 g/L)
  • Subjects receiving beta-blockers and/or diuretics
  • Subjects at high or very high cardiovascular risk according to ESC/EAS 2025 guidelines (assessed using the SCORE2 score, Appendix 2)
  • Subjects receiving anticoagulant therapy
  • Subjects receiving antiretroviral therapy
  • Subjects requiring immediate dietary intervention, or exhibiting fluctuating eating habits or an eating disorder (anorexia, bulimia, binge eating disorder)
  • Subjects on unstable treatment (initiated less than three months prior) or requiring the initiation of treatment during the study that, in the investigator's opinion, could interfere with the assessment of study endpoints (efficacy parameters: LDL, TG, HDL, blood glucose, blood pressure, weight; safety parameters: markers of hepatic, muscular, or renal function) Subjects who have consumed dietary supplements or functional foods capable of affecting cholesterol or triglyceride levels (phytosterols, phytostanols, red yeast rice, policosanols, beta-glucans at doses exceeding 3 g/day, artichoke or garlic extracts, probiotics, etc.) within the last 6 weeks
  • Subjects suffering from a severe chronic condition deemed incompatible with participation in the study by the investigator (serious digestive disorders, renal insufficiency, coronary artery disease, immunodeficiency, heart failure, rhythm disorders, active , hematological disease)
  • Subjects with an allergy to any of the components of LIPI-PROTECT-1
  • Pregnant or breastfeeding women, or women intending to become pregnant within the next 4 months
  • Subjects under legal protection (guardianship/curatorship, deprivation of liberty) or not covered by a social security scheme
  • Subjects participating in another clinical study or currently within the exclusion period of another study
  • Subjects whose condition is judged by the principal investigator or a qualified co-investigator deems that their health status or concomitant treatments are incompatible with the proper conduct of the clinical study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Food supplement group

    Three tablets of LIPI-PROTECT-1 per day (1 at the end or after breakfast and 2 during dinner). Food supplements are consumed during 3 months by healthy volunteers

    Dietary Supplement: LIPI-PROTECT-1

Interventions

  • Dietary supplementLIPI-PROTECT-1

    All subjects will consume 3 tablets per day during the entire intervention period, i.e. 12 weeks between V0 and V3, distributed as follows: 1 tablet in the morning at the end of or after breakfast (no taking on an empty stomach) and 2 tablets in the evening during dinner. If a dose is missed, 1 tablet can be taken at the next dose

06

What researchers measure

Primary outcomes

  1. To evaluate the effect of LIPI-PROTECT-1 on plasma LDL-cholesterol concentration (absolute value) after 3 months of consumption in subjects with untreated moderate hypercholesterolemia

    To evaluate the absolute (g/L) change in plasma LDL-cholesterol concentration, measured using the Friedewald method, between baseline (V0) and the end of the 3-month intervention (V3).

    Time frame: To baseline at 3 months

Secondary outcomes

  1. To evaluate the effect of LIPI-PROTECT-1 on plasma LDL-cholesterol concentration (relative value) after 3 months of consumption in subjects with untreated moderate hypercholesterolemia.

    To evaluate the relative (%) change in plasma LDL-cholesterol concentration, measured using the Friedewald method, between baseline (V0) and the end of the 3-month intervention (V3).

    Time frame: To baseline at 3 months

  2. To evaluate the effect of LIPI-PROTECT-1 on LDL cholesterol.

    Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in LDL cholesterol in g/L.

    Time frame: At baseline, 1 month and 3 months

  3. To evaluate the effect of LIPI-PROTECT-1 on Non HDL cholesterol.

    Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in Non HDL cholesterol in g/L.

    Time frame: At baseline, 1 month and 3 months

  4. To evaluate the effect of LIPI-PROTECT-1 on total cholesterol.

    Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in total cholesterol in g/L.

    Time frame: At baseline, 1 month and 3 months

  5. To evaluate the effect of LIPI-PROTECT-1 on HDL cholesterol.

    Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in HDL cholesterol in g/L.

    Time frame: At baseline, 1 month and 3 months

  6. To evaluate the effect of LIPI-PROTECT-1 on triglycerides.

    Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on triglycerides in g/L.

    Time frame: At baseline, 1 month and 3 months

  7. To evaluate the effect of LIPI-PROTECT-1 on non HDL cholesterol/LDL (atherogenic index).

    Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on non HDL cholesterol/LDL (atherogenic index) (ratio).

    Time frame: At baseline, 1 month and 3 months

  8. To evaluate the effect of LIPI-PROTECT-1 on ratio LDL/HDL.

    Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on non ratio LDL/HDL (ratio).

    Time frame: At baseline, 1 month and 3 months

  9. To evaluate the effect of LIPI-PROTECT-1 on ratio total cholesterol/HDL.

    Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on ratio total cholesterol/HDL (ratio).

    Time frame: At baseline, 1 month and 3 months

  10. To evaluate the effect of LIPI-PROTECT-1 on fasting blood glucose levels.

    Variation in fasting blood glucose (unit: g/l) between VS, V1, and V3

    Time frame: At baseline, 1 month and 3 months

  11. To evaluate the effect of LIPI-PROTECT-1 on weight.

    Changes in weight (unit : kilograms) between baseline, V1, and V3.

    Time frame: At baseline, 1 month and 3 months

  12. To evaluate the effect of LIPI-PROTECT-1 on Body Mass Index (BMI).

    Changes in BMI (weight and height will be combined to report BMI) in kg/m\^2between baseline, V1, and V3.

    Time frame: At baseline, 1 month and 3 months

  13. To evaluate the effect of LIPI-PROTECT-1 on waist circumference.

    Changes in waist circumference (unit: cm) between baseline, V1, and V3.

    Time frame: At baseline, 1 month and 3 months

  14. To evaluate the effect of LIPI-PROTECT-1 on arterial blood pressure

    Variation in systolic blood pressure and diastolic blood pressure (unit: mm Hg) between baseline, V1, and V3.

    Time frame: At baseline, 1 month and 3 months

  15. To evaluate the effect of LIPI-PROTECT-1 on heart rate

    Variation in Heart rate (unit: Pul/min) between baseline, V1, and V3.

    Time frame: At baseline, 1 month and 3 months

  16. To evaluate the safety of LIPI-PROTECT-1 on hepatic metabolism: ASAT/ALAT, GGT

    Changes in safety biomarkers : ASAT/ALAT and GGT(unit: UI/l) between baseline and V3 .

    Time frame: At baseline, 1 month and 3 months

  17. To evaluate the safety of LIPI-PROTECT-1 on hepatic metabolism : Creatinine, bilirubin

    Changes in safety biomarkers : Creatinine, bilirubin (unit: mg/dl) between baseline and V3.

    Time frame: At baseline and 3 months

  18. To evaluate the safety of LIPI-PROTECT-1 on renal metabolism : Urea

    Changes in safety biomarkers : Urea (unit: mg/dl) between baseline and V3.

    Time frame: At baseline and 3 months

  19. To evaluate the safety of LIPI-PROTECT-1 on renal metabolism : Creatinine Phophoskinase (CPK)

    Changes in safety biomarkers : CPK (unit : UI/l) between baseline and V3.

    Time frame: At baseline and 3 months

  20. To evaluate the safety of LIPI-PROTECT-1 on Renal metabolism : Lactate Deshydrogenase (LDH)

    Changes in safety biomarkers : LDH (unit : UI/l) between baseline and V3.

    Time frame: At baseline and 3 months

  21. To assess adherence to LIPI-PROTECT-1 consumption by pillbox weighing

    Adherence assessed by weighing the pillbox at each visit and comparing the weight with the initial weight recorded at baseline (V0).

    Time frame: At baseline, 1 month and 3 months

  22. To assess self-reported adherence to LIPI-PROTECT-1 consumption

    Adherence assessed through participant self-reporting of supplement consumption and missed doses.

    Time frame: At 1 month, 2 months and 3 months

  23. To assess adherence to LIPI-PROTECT-1 consumption by counting returned tablets

    Adherence assessed by counting the remaining tablets returned by participants at the end of the study.

    Time frame: At 3 months

07

Study locations

2 sites
  • Prevention research center - Institut Pasteur de Lille
    Lille, Nord 59019, France
  • Biophysium
    Avignon, Vaucluse 84140, France
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jan 2027, 4 months after the start.

Of 134 non-industry interventional studies with no phase under Hypercholesterolemia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 36. This study's planned 4 months is below that.

Counting every sponsor, half of 152 studies reached it within 15 months; a quarter within 6 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 18, 2026
StartActual
Sep 18, 2026
Primary completionEst.
Jan 31, 2027
CompletionEst.
Mar 30, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07946458
Lead sponsor
Institut Pasteur de Lille
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Sep 18, 2026
Primary completion
Jan 31, 2027 (estimated)
Completion
Mar 30, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Coralie Berthier, PhD
study chair · Institut Pasteur de Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion